Condition: Locally Advanced Head and Neck Squamous Cell Carcinoma · Sponsor: Ming-Yuan Chen
This study is a randomized, open-label, multicenter phase III trial designed to systematically evaluate the efficacy and safety of perioperative neoadjuvant and adjuvant therapy with Becotatug vedotin in combination with PD-1 inhibitor versus PD-1 inhibitor alone in patients with EGFR-positive, CPS ≥ 1 resectable locally advanced head and neck squamous cell carcinoma .
This description comes directly from the study's public registry record.
Mingyuan Chen · +86 18124188280 · chmingy@mail.sysu.edu.cn
Rui You · +86 13580439820 · your5@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| The Fifth Affiliated Hospital,Sun Yat-sen University | Zhuhai, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07524452